PATENT CLAIM ANALYSIS

Application Number: 15899520
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "312000"]

Abstract:
The present invention relates to the use of ceranib-2 molecule in the treatment of lung cancer and breast cancer. At the same time, the present invention also describes the in vitro studies made by the inventors in this direction.

Claim (Index 4):
The method of  claim 1 , wherein the ceranib-2 molecule is used together with at least one other antineoplastic agent.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 88.0
- Lexical Diversity: 1.4
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['09841744', '14382546', '12807931', '10868094', '13814614']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7494520804960357
- 35 USC 102 Novelty (BERT): 0.4855525104087087
- Combined Prediction Score: 0.723062123487303
- Mean Citation Score: 156.38570399999998
- Max Citation Score: 159.49222
- Similarity Product: 107.1566678357172

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test